AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2025
Mar 5, 2025
32883_dirs_2025-03-05_9114bbc3-75a7-4678-b1f7-087294b219a6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2025-03-03
Reporting Person: Vu Quan Anh (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-03-03 | Stock Options | $30.93 | A | 25000 | Acquired | 2035-03-02 | Common Stock (25000) | Direct |
Footnotes
F1: On March 3, 2025, the reporting person was granted 25,000 stock options, vesting 6/48ths (15,625 shares) on September 2, 2025, and 1/48th every month thereafter until the stock option is fully vested on March 3, 2029.
More from Monopar Therapeutics
Regulatory Filings
2026
May 29
Regulatory Filings
2026
May 19
Interim / Quarterly Report
2026
May 14
Report Publication Announcement
2026
May 14
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 20
Annual Report
2026
Apr 1
Annual Report
2026
Mar 27
Director's Dealing
2026
Mar 4
Board/Management Information
2026
Mar 2